322,323 In two ACG position papers (2018 and 2021) on the management of IBS, loperamide is not recommended as a first-line therapy due to the limited trials and small number of patients included, as well as its inability to improve global IBS symptoms
It also includes GLP-1 companion products used during care
doi: 10.1210/jendso/bvad074, 105
[1] [5] La dosis se titula gradualmente para minimizar los efectos secundarios gastrointestinales, que son los ms comunes durante el inicio del tratamiento
is an editor of Diabetes Care but was not involved in any of the decisions regarding review of the manuscript or its acceptance
Positive effects observed in studies include: Reduced liver fat accumulation Lower ALT and AST levels in patients with fatty liver Improved insulin sensitivity, which reduces liver workload Decreased inflammation markers Research published in The Lancet found that semaglutide significantly reduced liver fat and improved fibrosis markers in patients with metabolic dysfunction-associated steatohepatitis (MASH)